A 75-year-old man with a genetic predisposition for Alzheimer’s has yet to show signs of the disease. Could this offer ...

Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $52 from $49 and keeps an Outperform rating on the shares. The company’s ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

New research suggests that consistent aerobic exercise could be a powerful tool in reducing the biological signs associated ...

BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to beat a 2025 sales consensus of $86 million.

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Cantor Fitzgerald analyst Josh Schimmer raised the firm’s price target on BridgeBio (BBIO) to $95 from $70 and keeps an Overweight rating on ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

The MIND diet combines the Mediterranean diet and the DASH diet to create a dietary pattern that focuses specifically on brain health. “MIND” stands for “Mediterranean-DASH Intervention for ...

Researchers from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) have found that tau protein and beta-amyloid – two pathological hallmarks of Alzheimer’s disease – ...

Altered cerebrospinal fluid (CSF) levels of amyloid-β (Aβ) and tau proteins have been found in PDD, with intermediate changes for Aβ42 in non-demented PD. The authors investigated whether AD-related ...